Table 3.

Multivariate Analysis of Mortality, PFS, and Acute GvHD

Variable	Mortality			PFS			Grade II-IV Acute GvHD
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Donor KIR2DL1
CC	1			1			1
RC	0.44	0.26 to 0.74	.0024	0.45	0.26 to 0.78	.0049	0.59	0.23 to 1.49	.26
RR	0.4	0.25 to 0.64	.0001	0.38	0.23 to 0.63	.0001	0.46	0.19 to 1.09	.08
Age, years
< 10	1						1
> 10	1.2	0.88 to 1.63	.24				1.54	0.98 to 2.42	.06
Race
Black	1			1			1
Other	0.66	0.38 to 1.15	.14	0.63	0.35 to 1.15	.13	0.92	0.39 to 2.2	.85
White	1.05	0.7 to 1.57	.81	1.07	0.69 to 1.66	.75	1.48	0.75 to 2.92	.26
Primary diseases
Nonmalignant	1						1
Hematologic malignancy	1.94	1.15 to 3.27	.013	1			1.54	0.8 to 2.96	.2
Solid tumors	3.55	1.83 to 6.89	.0001	1.49	0.87 to 2.54	.15	2.98	1.25 to 7.13	.01
Malignant diseases status
CR1				1
CR2				1.29	0.8 to 2.07	.3
CR3/CR4				1.31	0.62 to 2.76	.48
Refractory/progressive				1.34	0.88 to 2.02	.17
Conditioning intensity
Nonmyeloablative	1			1			1
Myeloablative	0.7	0.49 to 1.0	.049	0.67	0.46 to 0.99	.046	0.44	0.27 to 0.72	.001
T cell depleted
No	1			1
Yes	1.45	1.05 to 1.99	.023	1.3	0.92 to 1.85	.14

Abbreviations: CC, KIR2DL1-C²⁴⁵ homozygous; GvHD, graft-versus-host disease; HR, hazard ratio; PFS, progression-free survival; RC, KIR2DL1-R²⁴⁵/C²⁴⁵ heterozygous; RR, KIR2DL1-R²⁴⁵ homozygous.